Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

NCT00867061 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Mutual decision by site and sponsor because of difficulty recruiting Patients.

Conditions

Interventions

Sponsor

Traws Pharma, Inc.